Related Experiment Videos
Renal cancer: molecular mechanisms and newer therapeutic options
S Ananth Karumanchi1, Jaime Merchan, Vikas P Sukhatme
1Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA. sanath@caregroup.harvard.edu
Abstract:
Renal cell carcinomas account for 80-85% of all primary renal neoplasms. Recent identification of VHL, c-met and TSC as candidate genes mutated in various types of renal carcinomas has greatly enhanced our understanding of the pathogenesis of renal carcinomas and has provided novel therapeutic options for patients with renal cancer. Furthermore, developments in angiogenesis and in tumor immunology have given us additional treatment modalities for cancer patients, especially those with renal cancer. This review highlights the genetic abnormalities seen in renal cell carcinomas and reviews current and future therapeutic options.
Insights
This review covers genetic mutations in renal cell carcinoma (RCC), a common kidney cancer. Understanding these genetic changes and advances in angiogenesis and immunology offers new therapeutic strategies for kidney cancer patients.
Area of Science:
- Oncology
- Genetics
- Nephrology
Background:
- Renal cell carcinoma (RCC) constitutes the vast majority (80-85%) of primary kidney tumors.
- Recent discoveries of mutated genes like VHL, c-met, and TSC have advanced the understanding of RCC pathogenesis.
- Progress in angiogenesis and tumor immunology research has opened new avenues for cancer treatment.
Purpose of the Study:
- To review the genetic abnormalities associated with renal cell carcinomas.
- To discuss current and emerging therapeutic strategies for renal cancer.
- To provide an overview of the molecular basis and treatment landscape of RCC.
Main Methods:
- Literature review of genetic abnormalities in renal cell carcinoma.
- Synthesis of information on VHL, c-met, and TSC gene mutations.
- Analysis of recent developments in angiogenesis and tumor immunology relevant to RCC treatment.
Main Results:
- Identification of key candidate genes (VHL, c-met, TSC) involved in renal carcinoma development.
- Demonstration of how genetic insights translate into novel therapeutic targets.
- Highlighting the impact of angiogenesis and immunology on treatment modalities for kidney cancer.
Conclusions:
- Genetic abnormalities are central to renal cell carcinoma pathogenesis.
- Targeted therapies based on genetic profiles are increasingly important.
- Advances in angiogenesis and immunology offer promising future treatments for renal cancer.